Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study aims to define a safe prophylactic intravenous TXA dose with an advantage over others in reducing total blood loss volume at secondary uncomplicated LSCS.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Talkha Central Hospital
• Collaborator: Al-Azhar University
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Pharmaceutical Solutions; Tranexamic Acid

Criteria

Inclusion Criteria:

• Maternal average age of 20-40 years.

• Singleton pregnancy at term between 38±5 days and 40 weeks.

• Elective planned or emergency secondary lower segment caesarean sections (LSCS).

Exclusion Criteria:

• Women with severe medical and surgical complications as any of the following will be excluded :

• Heart, liver, kidney, or brain diseases, and blood disorders.

• Abruptio placenta, and placental abnormalities or accrete syndromes.

• Polyhydramnios, macrosomia, preeclampsia, or allergy to tranexamic acid.

• History of thromboembolic disorders, or severe anemia.